Search Results - "Verschuuren, Jan"

Myasthenia gravis: subgroup classification and therapeutic strategies by Gilhus, Nils Erik, Prof, Verschuuren, Jan J, Prof

“…Summary Myasthenia gravis is an autoimmune disease that is characterised by muscle weakness and fatigue, is B-cell mediated, and is associated with antibodies…”
Get full text

Myasthenia gravis by Gilhus, Nils Erik, Tzartos, Socrates, Evoli, Amelia, Palace, Jacqueline, Burns, Ted M., Verschuuren, Jan J. G. M.

“…Myasthenia gravis (MG) is an autoimmune disease caused by antibodies against the acetylcholine receptor (AChR), muscle-specific kinase (MuSK) or other…”
Get full text

Population-based incidence and prevalence of facioscapulohumeral dystrophy by Deenen, Johanna C.W, Arnts, Hisse, van der Maarel, Silvère M, Padberg, George W, Verschuuren, Jan J.G.M, Bakker, Egbert, Weinreich, Stephanie S, Verbeek, André L.M, van Engelen, Baziel G.M

“…OBJECTIVE:To determine the incidence and prevalence of facioscapulohumeral muscular dystrophy (FSHD) in the Netherlands. METHODS:Using 3-source…”
Get full text

Lambert–Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies by Titulaer, Maarten J, Dr, Lang, Bethan, PhD, Verschuuren, Jan JGM, Prof

“…Summary Lambert–Eaton myasthenic syndrome (LEMS) is a neuromuscular autoimmune disease that has served as a model for autoimmunity and tumour immunology. In…”
Get full text

Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4 by Verschuuren, Jan J.G.M, Huijbers, Maartje G, Plomp, Jaap J, Niks, Erik H, Molenaar, Peter C, Martinez-Martinez, Pilar, Gomez, Alejandro M, De Baets, Marc H, Losen, Mario

“…Abstract Myasthenia gravis is caused by antibodies to the acetylcholine receptor, muscle-specific kinase, low-density lipoprotein receptor-related protein 4,…”
Get full text

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis by Howard, James F, Bril, Vera, Burns, Ted M, Mantegazza, Renato, Bilinska, Malgorzata, Szczudlik, Andrzej, Beydoun, Said, Garrido, Francisco Javier Rodriguez De Rivera, Piehl, Fredrik, Rottoli, Mariarosa, Van Damme, Philip, Vu, Tuan, Evoli, Amelia, Freimer, Miriam, Mozaffar, Tahseen, Ward, E Sally, Dreier, Torsten, Ulrichts, Peter, Verschueren, Katrien, Guglietta, Antonio, de Haard, Hans, Leupin, Nicolas, Verschuuren, Jan J.G.M

“…OBJECTIVETo investigate safety and explore efficacy of efgartigimod (ARGX-113), an anti-neonatal Fc receptor immunoglobulin G1 Fc fragment, in patients with…”
Get full text

A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities by Cox, Fieke M., Titulaer, Maarten J., Sont, Jacob K., Wintzen, Axel R., Verschuuren, Jan J. G. M., Badrising, Umesh A.

“…Sporadic inclusion body myositis is considered to be a slowly progressive myopathy. Long-term follow-up data are, however, not yet available. Follow-up data…”
Get full text

Increased risk for clinical onset of myasthenia gravis during the postpartum period by Boldingh, Marion I, Maniaol, Angelina H, Brunborg, Cathrine, Weedon-Fekjær, Harald, Verschuuren, Jan J.G.M, Tallaksen, Chantal M.E

“…OBJECTIVE:To study the risk of clinical onset of myasthenia gravis (MG) in pregnancy and during the first 6 months postpartum because an association between…”
Get full text

Fatigue in patients with myasthenia gravis. A systematic review of the literature by Ruiter, Annabel M., Verschuuren, Jan J.G.M., Tannemaat, Martijn R.

“…•Central fatigue is highly prevalent in autoimmune Myasthenia Gravis.•There is a strong association with disease severity, female gender and depressive…”
Get full text

Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders by Verschuuren, Jan JGM, Palace, Jacqueline, Murai, Hiroyuki, Tannemaat, Martijn R, Kaminski, Henry J, Bril, Vera

“…Myasthenia gravis and Lambert-Eaton myasthenic syndrome are antibody-mediated autoimmune diseases of the neuromuscular junction that usually present with…”
Get full text

Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT) by Saccà, Francesco, Barnett, Carolina, Vu, Tuan, Peric, Stojan, Phillips, Glenn A., Zhao, Sihui, Qi, Cynthia Z., Gelinas, Deborah, Chiroli, Silvia, Verschuuren, Jan J. G. M.

“…There are substantial disease and health-related quality-of-life (HRQoL) burdens for many patients with myasthenia gravis (MG), especially for those whose…”
Get full text

Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids by Tannemaat, Martijn R., Verschuuren, Jan J.G.M.

“…•Prednisolone, the mainstay of treatment for MG, has major adverse effects on long term health.•Several drug trials have failed, possibly due to suboptimal…”
Get full text

Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy by Doorenweerd, Nathalie, Mahfouz, Ahmed, van Putten, Maaike, Kaliyaperumal, Rajaram, t’ Hoen, Peter A. C., Hendriksen, Jos G. M., Aartsma-Rus, Annemieke M., Verschuuren, Jan J. G. M., Niks, Erik H., Reinders, Marcel J. T., Kan, Hermien E., Lelieveldt, Boudewijn P. F.

“…Duchenne muscular dystrophy (DMD) is a muscular dystrophy with high incidence of learning and behavioural problems and is associated with neurodevelopmental…”
Get full text

Improved olefinic fat suppression in skeletal muscle DTI using a magnitude‐based dixon method by Burakiewicz, Jedrzej, Hooijmans, Melissa T., Webb, Andrew G., Verschuuren, Jan J.G.M., Niks, Erik H., Kan, Hermien E.

“…Purpose To develop a method of suppressing the multi‐resonance fat signal in diffusion‐weighted imaging of skeletal muscle. This is particularly important when…”
Get full text

The effectiveness and side effects of pyridostigmine in the treatment of myasthenia gravis: a cross-sectional study by Remijn-Nelissen, Linda, Verschuuren, Jan J.G.M., Tannemaat, Martijn R.

“…•The net benefit and effectiveness of pyridostigmine are moderate.•A quarter of all patients report side effects as the main reason to discontinue…”
Get full text

Multi‐parametric MR in Becker muscular dystrophy patients by Hooijmans, Melissa T., Froeling, Martijn, Koeks, Zaida, Verschuuren, Jan J.G.M., Webb, Andrew, Niks, Erik H., Kan, Hermien E.

“…Quantitative MRI and MRS of muscle are increasingly being used to measure individual pathophysiological processes in Becker muscular dystrophy (BMD). In…”
Get full text

Prevalence and associated factors of fatigue in autoimmune myasthenia gravis by Ruiter, Annabel M., Verschuuren, Jan J.G.M., Tannemaat, Martijn R.

“…•Fatigue is highly prevalent and increases with disease severity.•Quality of life decreases rapidly as fatigue increases.•Coping strategies differ between…”
Get full text

Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes by Graus, Francesc, Vogrig, Alberto, Muñiz-Castrillo, Sergio, Antoine, Jean-Christophe G., Desestret, Virginie, Dubey, Divyanshu, Giometto, Bruno, Irani, Sarosh R., Joubert, Bastien, Leypoldt, Frank, McKeon, Andrew, Prüss, Harald, Psimaras, Dimitri, Thomas, Laure, Titulaer, Maarten J., Vedeler, Christian A., Verschuuren, Jan J., Dalmau, Josep, Honnorat, Jerome

“…The contemporary diagnosis of paraneoplastic neurologic syndromes (PNSs) requires an increasing understanding of their clinical, immunologic, and oncologic…”
Get full text

Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models by van der Pijl, Elizabeth M., van Putten, Maaike, Niks, Erik H., Verschuuren, Jan J. G. M., Aartsma-Rus, Annemieke, Plomp, Jaap J.

“…Duchenne muscular dystrophy (DMD) is an X‐linked myopathy caused by dystrophin deficiency. Dystrophin is present intracellularly at the sarcolemma, connecting…”
Get full text

Long‐term follow‐up, quality of life, and survival of patients with Lambert‐Eaton myasthenic syndrome by Lipka, Alexander F., Boldingh, Marion I., van Zwet, Erik W., Schreurs, Marco W.J., Kuks, Jan B.M., Tallaksen, Chantal M., Titulaer, Maarten J., Verschuuren, Jan J.G.M.

“…OBJECTIVETo study survival and to characterize long-term functional impairments and health-related quality of life (HRQOL) of patients with Lambert-Eaton…”
Get full text